Brief: IGEA To Get Six Approval To Delay 2020 Annual Report Disclosure

IGEA Pharma NV

01/05/2021 01:48

April 30 (Reuters) - IGEA Pharma NV  IGPH.S :
    * IGEA TO GET SIX APPROVAL TO DELAY 2020 ANNUAL REPORT
DISCLOSURE
    * GRANT OF A TEMPORARY EXEMPTION FROM ITS DISCLOSURE
OBLIGATIONS
WITH RESPECT TO 2020 ANNUAL REPORT.
    * IGEA EXPECTS TO DISCLOSE ITS 2020 ANNUAL REPORT WITHIN
NEXT
COMING WEEKS
    * IGEA PHARMA- UNAUDITED FIGURES FOR 2020 ARE ANTICIPATED AS
GROUP
GENERATED MARGINAL REVENUE OF TUSD 79
    * FY 2020 COST OF SALES WAS TUSD 291 (2019: TUSD 440)
    * FY 2020 OPERATING EXPENSES WERE TUSD 753 (2019: TUSD
1'491)
    * IGEA- 2020 EBITDA AS ADJUSTED (BEFORE IMPAIRMENT CHARGES)
AND
EBIT IS TUSD -1'040 (2019: TUSD -1'617) AND TUSD -1,135 (2019:
TUSD -1,930) RESPECTIVELY
    * FY 2020 NET LOSS IS TUSD 1'140 (2019: TUSD 1,908)

Source text for Eikon:  ID:nEQ3qwq5a 
Further company coverage:  IGPH.S 

 ((Reuters.Briefs@thomsonreuters.com;))